Vvax001 Cancer Vaccine in Premalignant Cervical Lesions - Phase II

Inclusion Criteria: * Newly diagnosed HPV16-positive CIN3. * Age of 18 years and older. * Patients of child-bearing potential should test negative using a serum pregnancy test and agree to utilize effective contraception during the entire treatment and follow-up period of the study. * Written informed consent according to local guidelines. Exclusion Criteria: * PAP5 lesions. * Previously undergone treatment for CIN lesions. * Adenocarcinoma in situ within CIN3 lesion. * History of an autoimmune disease or other systemic intercurrent disease that might affect the immunocompetence of the patient, or current or prior use (4 weeks before start of the study) of high dose immunosuppressive therapy. * History of a malignancy except curatively treated low-stage tumors with a histology that can be differentiated from the cervical cancer type. * Participation in a study with another investigational drug within 30 days prior to the enrolment in this study. * Clinically significant findings as judged by the Investigator on screening/study entry including those from the Biochemistry, Hematology and urinalysis performed at baseline. * Any condition that in the opinion of the investigator could interfere with the conduct of the study. * Pregnancy.